Tempest Therapeutics, Inc. (TPST)
0.873
-0.04
(-3.95%)
USD |
NASDAQ |
Sep 10, 12:06
Tempest Therapeutics Enterprise Value : 21.30M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 21.30M |
| September 08, 2026 | 22.56M |
| September 04, 2026 | 23.24M |
| September 03, 2026 | 23.56M |
| September 02, 2026 | 24.36M |
| September 01, 2026 | 23.56M |
| August 31, 2026 | 24.20M |
| August 28, 2026 | 23.72M |
| August 27, 2026 | 24.04M |
| August 26, 2026 | 24.04M |
| August 25, 2026 | 24.52M |
| August 24, 2026 | 24.36M |
| August 21, 2026 | 23.40M |
| August 20, 2026 | 23.08M |
| August 19, 2026 | 23.88M |
| August 18, 2026 | 23.88M |
| August 17, 2026 | 24.84M |
| August 14, 2026 | 23.00M |
| August 13, 2026 | 25.48M |
| August 12, 2026 | 26.12M |
| August 11, 2026 | 25.64M |
| August 10, 2026 | 23.40M |
| August 07, 2026 | 21.43M |
| August 06, 2026 | 21.20M |
| August 05, 2026 | 21.39M |
| Date | Value |
|---|---|
| August 04, 2026 | 20.96M |
| August 03, 2026 | 20.76M |
| July 31, 2026 | 20.46M |
| July 30, 2026 | 20.58M |
| July 29, 2026 | 21.04M |
| July 28, 2026 | 20.70M |
| July 27, 2026 | 21.72M |
| July 24, 2026 | 21.58M |
| July 23, 2026 | 21.81M |
| July 22, 2026 | 21.98M |
| July 21, 2026 | 22.60M |
| July 20, 2026 | 22.00M |
| July 17, 2026 | 22.22M |
| July 16, 2026 | 22.38M |
| July 15, 2026 | 23.88M |
| July 14, 2026 | 22.45M |
| July 13, 2026 | 22.50M |
| July 10, 2026 | 22.33M |
| July 09, 2026 | 22.36M |
| July 08, 2026 | 22.56M |
| July 07, 2026 | 22.62M |
| July 06, 2026 | 23.88M |
| July 02, 2026 | 24.20M |
| July 01, 2026 | 24.52M |
| June 30, 2026 | 24.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.882B |
| Alnylam Pharmaceuticals, Inc. | 34.18B |
| Anika Therapeutics, Inc. | 266.28M |
| Savara, Inc. | 969.61M |
| Vericel Corp. | 1.927B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.244M |
| Total Expenses (Quarterly) | 5.244M |
| EPS Diluted (Quarterly) | -0.3445 |
| Earnings Yield | -513.7% |
| Normalized Earnings Yield | -351.04 |